HepeX-C (XTL Biopharmaceuticals).
XTL Biopharmaceuticals is developing HepeX-C, a combination of two antibodies (HCV-AB68 and HCV-AB65) as a potential therapy for hepatitis C virus infection. By September 2003, phase II trials of HCV-AB68 alone had been conducted and XTL Biopharmaceuticals announced that it planned to conduct a phase I study of the antibody combination.
Borgia
Guglielmo
G
Department of Public Medicine and Social Security, Institute for Infectious Diseases-Ed 18, University of Naples Federico II, via S Pansini 5, 80131 Naples, Italy. borgia@unina.it
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004338:Drug Combinations; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D010330:Patents as Topic; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D004338:Drug Combinations